Filing Details

Accession Number:
0001209191-23-020846
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-23 19:47:49
Reporting Period:
2023-03-21
Accepted Time:
2023-03-23 19:47:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1863127 Tyra Biosciences Inc. TYRA Pharmaceutical Preparations (2834) 831476348
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1880946 Daniel Bensen C/O Tyra Biosciences, Inc.
2656 State Street
Carlsbad CA 92008
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-21 14,100 $0.61 542,081 No 4 M Direct
Common Stock Disposition 2023-03-21 14,100 $16.00 527,981 No 4 S Direct
Common Stock Acquisiton 2023-03-22 3,800 $0.61 531,781 No 4 M Direct
Common Stock Disposition 2023-03-22 3,800 $16.00 527,981 No 4 S Direct
Common Stock Acquisiton 2023-03-23 4,827 $0.61 532,808 No 4 M Direct
Common Stock Disposition 2023-03-23 4,827 $16.00 527,981 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-03-21 14,100 $0.00 14,100 $0.61
Common Stock Stock Option (Right to Buy) Disposition 2023-03-22 3,800 $0.00 3,800 $0.61
Common Stock Stock Option (Right to Buy) Disposition 2023-03-23 4,827 $0.00 4,827 $0.61
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
256,029 2030-01-26 No 4 M Direct
252,229 2030-01-26 No 4 M Direct
247,402 2030-01-26 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022.
  2. 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.